Cargando…
Development of models for cervical cancer screening: construction in a cross-sectional population and validation in two screening cohorts in China
BACKGROUND: Current methods for cervical cancer screening result in an increased number of referrals and unnecessary diagnostic procedures. This study aimed to develop and evaluate a more accurate model for cervical cancer screening. METHODS: Multiple predictors including age, cytology, high-risk hu...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414700/ https://www.ncbi.nlm.nih.gov/pubmed/34474668 http://dx.doi.org/10.1186/s12916-021-02078-2 |
_version_ | 1783747832368332800 |
---|---|
author | Wu, Zeni Li, Tingyuan Han, Yongli Jiang, Mingyue Yu, Yanqin Xu, Huifang Yu, Lulu Cui, Jianfeng Liu, Bin Chen, Feng Yin, Jian Zhang, Xun Pan, Qinjing Qiao, Youlin Chen, Wen |
author_facet | Wu, Zeni Li, Tingyuan Han, Yongli Jiang, Mingyue Yu, Yanqin Xu, Huifang Yu, Lulu Cui, Jianfeng Liu, Bin Chen, Feng Yin, Jian Zhang, Xun Pan, Qinjing Qiao, Youlin Chen, Wen |
author_sort | Wu, Zeni |
collection | PubMed |
description | BACKGROUND: Current methods for cervical cancer screening result in an increased number of referrals and unnecessary diagnostic procedures. This study aimed to develop and evaluate a more accurate model for cervical cancer screening. METHODS: Multiple predictors including age, cytology, high-risk human papillomavirus (hrHPV) DNA/mRNA, E6 oncoprotein, HPV genotyping, and p16/Ki-67 were used for model construction in a cross-sectional population including women with normal cervix (N = 1085), cervical intraepithelial neoplasia (CIN, N = 279), and cervical cancer (N = 551) to predict CIN2+ or CIN3+. A base model using age, cytology, and hrHPV was calculated, and extended versions with additional biomarkers were considered. External validations in two screening cohorts with 3-year follow-up were further conducted (N(Cohort-I) = 3179, N(Cohort-II) = 3082). RESULTS: The base model increased the area under the curve (AUC, 0.91, 95% confidence interval [CI] = 0.88–0.93) and reduced colposcopy referral rates (42.76%, 95% CI = 38.67–46.92) compared to hrHPV and cytology co-testing in the cross-sectional population (AUC 0.80, 95% CI = 0.79–0.82, referrals rates 61.62, 95% CI = 59.4–63.8) to predict CIN2+. The AUC further improved when HPV genotyping and/or E6 oncoprotein were included in the base model. External validation in two screening cohorts further demonstrated that our models had better clinical performances than routine screening methods, yielded AUCs of 0.92 (95% CI = 0.91–0.93) and 0.94 (95% CI = 0.91–0.97) to predict CIN2+ and referrals rates of 17.55% (95% CI = 16.24–18.92) and 7.40% (95% CI = 6.50–8.38) in screening cohort I and II, respectively. Similar results were observed for CIN3+ prediction. CONCLUSIONS: Compared to routine screening methods, our model using current cervical screening indicators can improve the clinical performance and reduce referral rates. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-021-02078-2. |
format | Online Article Text |
id | pubmed-8414700 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84147002021-09-09 Development of models for cervical cancer screening: construction in a cross-sectional population and validation in two screening cohorts in China Wu, Zeni Li, Tingyuan Han, Yongli Jiang, Mingyue Yu, Yanqin Xu, Huifang Yu, Lulu Cui, Jianfeng Liu, Bin Chen, Feng Yin, Jian Zhang, Xun Pan, Qinjing Qiao, Youlin Chen, Wen BMC Med Research Article BACKGROUND: Current methods for cervical cancer screening result in an increased number of referrals and unnecessary diagnostic procedures. This study aimed to develop and evaluate a more accurate model for cervical cancer screening. METHODS: Multiple predictors including age, cytology, high-risk human papillomavirus (hrHPV) DNA/mRNA, E6 oncoprotein, HPV genotyping, and p16/Ki-67 were used for model construction in a cross-sectional population including women with normal cervix (N = 1085), cervical intraepithelial neoplasia (CIN, N = 279), and cervical cancer (N = 551) to predict CIN2+ or CIN3+. A base model using age, cytology, and hrHPV was calculated, and extended versions with additional biomarkers were considered. External validations in two screening cohorts with 3-year follow-up were further conducted (N(Cohort-I) = 3179, N(Cohort-II) = 3082). RESULTS: The base model increased the area under the curve (AUC, 0.91, 95% confidence interval [CI] = 0.88–0.93) and reduced colposcopy referral rates (42.76%, 95% CI = 38.67–46.92) compared to hrHPV and cytology co-testing in the cross-sectional population (AUC 0.80, 95% CI = 0.79–0.82, referrals rates 61.62, 95% CI = 59.4–63.8) to predict CIN2+. The AUC further improved when HPV genotyping and/or E6 oncoprotein were included in the base model. External validation in two screening cohorts further demonstrated that our models had better clinical performances than routine screening methods, yielded AUCs of 0.92 (95% CI = 0.91–0.93) and 0.94 (95% CI = 0.91–0.97) to predict CIN2+ and referrals rates of 17.55% (95% CI = 16.24–18.92) and 7.40% (95% CI = 6.50–8.38) in screening cohort I and II, respectively. Similar results were observed for CIN3+ prediction. CONCLUSIONS: Compared to routine screening methods, our model using current cervical screening indicators can improve the clinical performance and reduce referral rates. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-021-02078-2. BioMed Central 2021-09-03 /pmc/articles/PMC8414700/ /pubmed/34474668 http://dx.doi.org/10.1186/s12916-021-02078-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Wu, Zeni Li, Tingyuan Han, Yongli Jiang, Mingyue Yu, Yanqin Xu, Huifang Yu, Lulu Cui, Jianfeng Liu, Bin Chen, Feng Yin, Jian Zhang, Xun Pan, Qinjing Qiao, Youlin Chen, Wen Development of models for cervical cancer screening: construction in a cross-sectional population and validation in two screening cohorts in China |
title | Development of models for cervical cancer screening: construction in a cross-sectional population and validation in two screening cohorts in China |
title_full | Development of models for cervical cancer screening: construction in a cross-sectional population and validation in two screening cohorts in China |
title_fullStr | Development of models for cervical cancer screening: construction in a cross-sectional population and validation in two screening cohorts in China |
title_full_unstemmed | Development of models for cervical cancer screening: construction in a cross-sectional population and validation in two screening cohorts in China |
title_short | Development of models for cervical cancer screening: construction in a cross-sectional population and validation in two screening cohorts in China |
title_sort | development of models for cervical cancer screening: construction in a cross-sectional population and validation in two screening cohorts in china |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414700/ https://www.ncbi.nlm.nih.gov/pubmed/34474668 http://dx.doi.org/10.1186/s12916-021-02078-2 |
work_keys_str_mv | AT wuzeni developmentofmodelsforcervicalcancerscreeningconstructioninacrosssectionalpopulationandvalidationintwoscreeningcohortsinchina AT litingyuan developmentofmodelsforcervicalcancerscreeningconstructioninacrosssectionalpopulationandvalidationintwoscreeningcohortsinchina AT hanyongli developmentofmodelsforcervicalcancerscreeningconstructioninacrosssectionalpopulationandvalidationintwoscreeningcohortsinchina AT jiangmingyue developmentofmodelsforcervicalcancerscreeningconstructioninacrosssectionalpopulationandvalidationintwoscreeningcohortsinchina AT yuyanqin developmentofmodelsforcervicalcancerscreeningconstructioninacrosssectionalpopulationandvalidationintwoscreeningcohortsinchina AT xuhuifang developmentofmodelsforcervicalcancerscreeningconstructioninacrosssectionalpopulationandvalidationintwoscreeningcohortsinchina AT yululu developmentofmodelsforcervicalcancerscreeningconstructioninacrosssectionalpopulationandvalidationintwoscreeningcohortsinchina AT cuijianfeng developmentofmodelsforcervicalcancerscreeningconstructioninacrosssectionalpopulationandvalidationintwoscreeningcohortsinchina AT liubin developmentofmodelsforcervicalcancerscreeningconstructioninacrosssectionalpopulationandvalidationintwoscreeningcohortsinchina AT chenfeng developmentofmodelsforcervicalcancerscreeningconstructioninacrosssectionalpopulationandvalidationintwoscreeningcohortsinchina AT yinjian developmentofmodelsforcervicalcancerscreeningconstructioninacrosssectionalpopulationandvalidationintwoscreeningcohortsinchina AT zhangxun developmentofmodelsforcervicalcancerscreeningconstructioninacrosssectionalpopulationandvalidationintwoscreeningcohortsinchina AT panqinjing developmentofmodelsforcervicalcancerscreeningconstructioninacrosssectionalpopulationandvalidationintwoscreeningcohortsinchina AT qiaoyoulin developmentofmodelsforcervicalcancerscreeningconstructioninacrosssectionalpopulationandvalidationintwoscreeningcohortsinchina AT chenwen developmentofmodelsforcervicalcancerscreeningconstructioninacrosssectionalpopulationandvalidationintwoscreeningcohortsinchina |